05:46:26 EDT Mon 15 Aug 2022
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Avicanna Inc
Symbol AVCN
Shares Issued 45,858,596
Close 2021-12-06 C$ 0.81
Recent Sedar Documents

Avicanna files oral cannabinoid technology patent

2021-12-06 10:49 ET - News Release

Mr. Aras Azadian reports

AVICANNA FILES A PATENT TO PROTECT ITS ADVANCED ORAL CANNABINOID PLATFORM AND ITS APPLICATIONS FOR NEUROLOGICAL DISEASES

Avicanna Inc. has filed a provisional patent application in the United States Patent and Trademark Office for a novel oral cannabinoid technology, which is intended to be commercialized globally for medical and pharmaceutical applications, including treatment of various neurological diseases and disorders.

Oral administration of cannabinoids is the most convenient route for non-invasive drug delivery. However, due to the highly lipophilic nature and poor water solubility of cannabinoids, the elementary formulations currently available on the market generally have poor bioavailability and lack consistent drug delivery. Avicanna's proprietary compositions have been specifically designed to alter the hydrophobic nature of cannabinoids, resulting in enhanced drug solubility which leads to better absorption and bioavailability either sublingually or orally, thereby increasing efficacy of cannabinoids.

"Our novel formulations overcome the current limitations of cannabinoid finished products in the market today and offer enhanced absorption of varying cannabinoid profiles with controlled delivery. We expect this will yield better patient outcomes and clinical results," stated Dr. Frantz Le Devedec, executive vice-president of research and product development at Avicanna.

The patent application, entitled "Oral cannabinoid compositions and methods of treating neurological diseases and disorders," claims formulations that have been developed through Avicanna's R&D (research and development) platform utilizing the company's proprietary self-emulsifying drug delivery systems (SEDDS) technology and include a range of drug delivery formats with varying release and absorption profiles, including:

  • Sustained and controlled-release tablets -- designed for linear release of the drug over time and thereby maximizing pharmacological properties and reducing side effects particular to cannabinoids;
  • Oral capsules -- self-emulsifying cannabinoid technology designed to enhance absorption through a fast and effective dispersion mechanism;
  • Sublingual tablets -- designed to provide rapid absorption of cannabinoids through the sublingual membrane to reduce first-pass metabolism and provide a solution for acute symptom management;
  • Water-soluble formulations -- nano-emulsion technology designed for instant dispersion and dissolution of cannabinoids which can be utilized for convenient titration in drug delivery and beverages.

"This patent submission is another example of our drug delivery platforms used to develop industry-leading products as we continue to innovate and lead the path with advanced, standardized and evidenced-based cannabinoid solutions. We are optimistic about the potential of these formulations across several of our commercial and clinical platforms globally," stated Aras Azadian, chief executive officer of Avicanna.

Avicanna intends to conduct further preclinical studies in the coming months in order to formalize this provisional application and will incorporate the technology into its clinical pipeline in 2022. If granted, this patent application will provide Avicanna with protection on the use of the formulation candidates for neurological diseases, alone or in combination with other therapies.

About Avicanna Inc.

Avicanna is a Canadian commercial-stage biopharmaceutical company established in cannabinoid research, development and evidence-based products for the global consumer, as well as medical and pharmaceutical market segments. In leading global cannabinoid advancements, Avicanna conducts most of its research in Canada at its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, located in the MaRS discovery district. The company actively collaborates with leading Canadian academic and medical institutions. Avicanna has established an industry-leading scientific platform, including advanced R&D and clinical development which has led to the commercialization of over 20 products across four main market segments.

We seek Safe Harbor.

© 2022 Canjex Publishing Ltd. All rights reserved.